1239492-22-8 Usage
Description
2-Bromo-1-(difluoromethoxy)-3-fluorobenzene is an organic compound characterized by its unique molecular structure, which features a bromine atom, a difluoromethoxy group, and a fluorine atom attached to a benzene ring. 2-BroMo-1-(difluoroMethoxy)-3-fluorobenzene is known for its potential applications in the pharmaceutical and chemical industries due to its versatile chemical properties.
Uses
Used in Pharmaceutical Industry:
2-Bromo-1-(difluoromethoxy)-3-fluorobenzene is used as a key intermediate in the synthesis of acylguanidine derivatives. These derivatives act as modulators for the 5-HT5A receptor, which plays a crucial role in the regulation of various neurological processes. The compound is utilized for the development of potential therapeutic agents for the treatment or prevention of neuropsychiatric disorders such as dementia, schizophrenia, and bipolar disorder.
Check Digit Verification of cas no
The CAS Registry Mumber 1239492-22-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,9,4,9 and 2 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1239492-22:
(9*1)+(8*2)+(7*3)+(6*9)+(5*4)+(4*9)+(3*2)+(2*2)+(1*2)=168
168 % 10 = 8
So 1239492-22-8 is a valid CAS Registry Number.
1239492-22-8Relevant articles and documents
THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS
-
Paragraph 0411, (2020/12/11)
Disclosed herein are certain thiadiazolyl derivatives Formula (I): that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.
FACTOR XIa INHIBITORS
-
Page/Page column 59, (2017/05/21)
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.
